09/01/2026
The Cambridge-led IVORY trial, supported by NIHR Cambridge Clinical Research Facility, has shown that targeting the immune system, by giving a low-dose of aldesleukin, could prevent future heart attacks by nearly 11%.
Learn more about the study >> https://www.cambridgecrf.nihr.ac.uk/2026/01/08/targeting-the-immune-system-could-prevent-future-heart-attacks-cambridge-led-trial-suggests/
NIHR Cambridge Biomedical Research Centre Cambridge University Hospitals NHS Foundation Trust University of Cambridge National Institute for Health and Care Research Royal Papworth Hospital
Cambridge researchers have discovered that an existing therapy which boosts protective immune cells in people who have recently had heart attacks reduces blood vessel inflammation and may reduce the likelihood of future heart attacks.